The recently published data from the seminal CheckMate 067 clinical trial have demonstrated median melanoma-specific survival of more than 120 months for combined ICI therapy (nivolumab (PD1 inhibitor)) plus ipilimumab (CTLA4 inhibitor) and 50 months for PD-1 inhibitor-based monotherapy [2]. The gene discussed is PDCD1; the disease is melanoma.